中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(4): 798-804

Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review

DOI: 10.3969/j.issn.1001-5256.2022.04.012
  • a.

    Department of Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

  • b.

    Department of Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

  • c.

    Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

  • d.

    Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

  • e.

    National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Research funding:

National Natural Science Foundation of China (82130018);

Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXZ03);

Beijing research ward demonstration construction project (BCRW202010)

More Information
    Abstract
  •   Objective  To describe the characteristics and registration status of clinical trials of new drugs for nonalcoholic steatohepatitis (NASH), and to provide a reference for the design and implementation of clinical trials of new drugs for NASH.  Methods  The U.S. Clinical Trials Database, China Clinical Trial Registry, and Center for Drug Evaluation, National Medical Products Administration, were searched for clinical trials of new drug registration and interventional studies with NASH as the indication published up to August 6, 2021, using NASH in English and Chinese characters as the keywords, and liver cirrhosis was excluded. Two researchers independently searched and screened the articles to extract relevant information.  Results  A total of 196 clinical trials of new drug registration or interventional studies for NASH were included, among which there were 174 trials registered abroad and 22 trials registered in China, and the number of registrations tended to increase year by year. The numbers of phase Ⅰ, phase Ⅰ/Ⅱ(including Ⅰb/Ⅱa), phase Ⅱ, phase Ⅱ/Ⅲ, and phase Ⅲ clinical trials were 45(23.0%), 8(4.1%), 112(57.1%), 4(2.0%), and 19(9.7%), respectively. The main drug types included farnesoid X receptors, fibroblast growth factors, peroxisome proliferator-activated receptor agonists, and glucagon-like peptide-1, with numbers of 16(8.16%), 14(7.14%), 11(5.61%), and 13(6.63%), respectively. The clinical trials of innovative drugs for NASH initiated by the sponsors in European and American regions accounted for the highest proportion, and there was a gradual increase in the number of clinical trials of innovative drugs in China in recent years, with a similar distribution of single-center and multicenter clinical trials. As for the trials with NASH patients as subjects, the numbers of trials with pathology, imaging, and clinical diagnosis as the main inclusion criteria were 125, 66, and 42, respectively. Phase Ⅰ clinical trials used safety, tolerability, and pharmacokinetic parameters as the main assessment indices, while phase Ⅱ and phase Ⅲ clinical trials often used safety and efficacy as the main assessment indices. The number of clinical trials for the registration of innovative drugs for NASH was relatively low but kept increasing in China, and there were fewer clinical trials of innovative traditional Chinese medicine drugs compared with innovative chemical drugs.  Conclusion  There is a significant increase in the registration of international clinical trials of innovative drugs for NASH, and most of these trials are in the early phases, with large differences in inclusion criteria and assessment indices, a lack of unified evaluation indices, and relatively few trials with new designs. There are fewer clinical trials of innovative drugs for NASH in China than in European and American countries, and the number of such trials is gradually increasing in China.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [2]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
    [3]
    SANYAL AJ, FRIEDMAN SL, MCCULLOUGH AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop[J]. Hepatology, 2015, 61(4): 1392-1405. DOI: 10.1002/hep.27678.
    [4]
    LAZARIDIS N, TSOCHATZIS E. Current and future treatment options in non-alcoholic steatohepatitis (NASH)[J]. Expert Rev Gastroenterol Hepatol, 2017, 11(4): 357-369. DOI: 10.1080/17474124.2017.1293523.
    [5]
    ANANIA FA, DIMICK-SANTOS L, MEHTA R, et al. Nonalcoholic steatohepatitis: Current thinking from the division of hepatology and nutrition at the food and drug administration[J]. Hepatology, 2021, 73(5): 2023-2027. DOI: 10.1002/hep.31687.
    [6]
    RINELLA ME, TACKE F, SANYAL AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD[J]. J Hepatol, 2019, 71(4): 823-833. DOI: 10.1016/j.jhep.2019.04.019.
    [7]
    China Food and Drug Administration. Guidelines for clinical trials of drugs for the treatment of non alcoholic steatohepatitis[EB/OL]. [2019-12-30]. http://www.nmpa.gov.cn/WS04/CL2138/372284.html.

    国家药品食品监督管理总局. 非酒精性脂肪性肝炎治疗药物临床试验指导原则(试行)[EB/OL]. [2019-12-30]. http://www.nmpa.gov.cn/WS04/CL2138/372284.html.
    [8]
    KLEINER DE, BRUNT EM, van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-1321. DOI: 10.1002/hep.20701.
    [9]
    KONERMAN MA, JONES JC, HARRISON SA. Pharmacotherapy for NASH: Current and emerging[J]. J Hepatol, 2018, 68(2): 362-375. DOI: 10.1016/j.jhep.2017.10.015.
    [10]
    REIMER KC, WREE A, RODERBURG C, et al. New drugs for NAFLD: Lessons from basic models to the clinic[J]. Hepatol Int, 2020, 14(1): 8-23. DOI: 10.1007/s12072-019-10001-4.
    [11]
    TONG XF, SUN YM, YOU H. Evaluation of clinical endpoints in new drug research and development for nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2021, 37(6): 1249-1253. DOI: 10.3969/j.issn.1001-5256.2021.06.003.

    佟小非, 孙亚朦, 尤红. 非酒精性脂肪性肝炎新药研发临床终点评价[J]. 临床肝胆病杂志, 2021, 37(6): 1249-1253. DOI: 10.3969/j.issn.1001-5256.2021.06.003.
    [12]
    DAVISON BA, HARRISON SA, COTTER G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials[J]. J Hepatol, 2020, 73(6): 1322-1332. DOI: 10.1016/j.jhep.2020.06.025.
    [13]
    CAUSSY C, REEDER SB, SIRLIN CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials[J]. Hepatology, 2018, 68(2): 763-772. DOI: 10.1002/hep.29797.
    [14]
    JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase Ⅱ trial of selonsertib[J]. J Hepatol, 2019, 70(1): 133-141. DOI: 10.1016/j.jhep.2018.09.024.
    [15]
    HOOKER JC, HAMILTON G, PARK CC, et al. Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis[J]. Abdom Radiol (NY), 2019, 44(2): 482-492. DOI: 10.1007/s00261-018-1745-3.
    [16]
    SASSO M, AUDIÈRE S, KEMGANG A, et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: A Pilot study assessing diagnostic accuracy[J]. Ultrasound Med Biol, 2016, 42(1): 92-103. DOI: 10.1016/j.ultrasmedbio.2015.08.008.
    [17]
    VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLA-BERTOT L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149(2): 367-378. e5; quiz e14-e15. DOI: 10.1053/j.gastro.2015.04.005.
    [18]
    ROMERO-GÓMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4): 829-846. DOI: 10.1016/j.jhep.2017.05.016.
    [19]
    SANYAL AJ, BRUNT EM, KLEINER DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis[J]. Hepatology, 2011, 54(1): 344-353. DOI: 10.1002/hep.24376.
    [20]
    RATZIU V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials[J]. J Hepatol, 2018, 68(2): 353-361. DOI: 10.1016/j.jhep.2017.12.001.
    [21]
    LICHTINGHAGEN R, PIETSCH D, BANTEL H, et al. The enhanced liver fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values[J]. J Hepatol, 2013, 59(2): 236-242. DOI: 10.1016/j.jhep.2013.03.016.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (965) PDF downloads(155) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return